Baxalta Inc (BXLT) : Lodestar Investment Counselil scooped up 885 additional shares in Baxalta Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 68,765 shares of Baxalta Inc which is valued at $2,845,496.Baxalta Inc makes up approximately 0.40% of Lodestar Investment Counselil’s portfolio.
Baxalta Inc closed down -0.42 points or -1.02% at $40.8 with 41,40,444 shares getting traded on Wednesday. Post opening the session at $41.03, the shares hit an intraday low of $40.69 and an intraday high of $41.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Lincluden Management Ltd sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 176,385 shares of BXLT which is valued $7,298,811. Murphy Pohlad Asset Management sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 52,871 shares of BXLT which is valued $2,187,802.Jacobs Coca reduced its stake in BXLT by selling 3,775 shares or 6.52% in the most recent quarter. The Hedge Fund company now holds 54,081 shares of BXLT which is valued at $2,190,821. Baxalta Inc makes up approx 0.52% of Jacobs Coca’s portfolio.Proficio Capital Partners boosted its stake in BXLT in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 153 shares of Baxalta Inc which is valued at $6,174. Baxalta Inc makes up approx 0.01% of Proficio Capital Partners’s portfolio.
On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.